Certain pharmacotherapies, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), have demonstrated potential in attenuating coronary artery inflammation in patients with T2DM (33, 34). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.